Scil Proteins today announced that it has concluded a financing round with its existing investor, BioNet Holding, worth €24 million. The funds are intended to finance the development of two Affilin® products. (full text)
11.08.2010:
Scil Proteins announced that it has completed the formation of its advisory board. The AB is comprised of two scientific experts in the field, Dr. Andreas Menrad and Dr. Jürgen Wahl, as well as the seasoned financial consultant Rainer Kroell. (pdf)
23.06.2010:
Scil Proteins Pharma has achieved validation of its proprietary Affilin® drug discovery platform in animals. The lead product, SPVF 2801, an Affilin® molecule for applications in solid tumors passed initial preclinical studies with excellent results. (pdf)
09.11.2009:
Bone marrow typing organised by Scil Proteins.
(pdf) (article in german)
14.09.2009:
Scil Proteins signed an agreement with ipal GmbH and Charité University Hospital, Berlin for the purchase of the Tat Phage display technique.
(pdf)
18.08.2009:
Dr. Henning Afflerbach was appointed as Chief Business Officer.
(pdf)
23.06.2009:
Frank Ubags is appointed as financial director of Scil Proteins GmbH and Scil Proteins Production GmbH.
(pdf)
28.06.2009:
Scil Proteins Production GmbH, the manufacturing site for Scil Proteins GmbH, has received the GMP certificate from the German regulatory authority of Saxony-Anhalt for the production of drug substances of microbiological origin.
(pdf)
01.02.2009:
Scil Proteins receives 1,6 M Euro grant to intensify research on the diagnosis and treatment of liver fibrosis.
(pdf)
24.06.2008:
Scil Proteins Production GmbH announces the closing of a protein production deal with Swiss pharmaceutical firm Roche.
(pdf)
19.07.2006:
Scil Proteins and Cambridge Antibody Technology (CAT) sign crosslicense agreement in the field of Affilin® technology and ribosome display.
(pdf)
18.05.2006:
Scil Proteins receives significant funding to strengthen in-house oncology programm.
(pdf)
